Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two rituximab regimens in lupus nephritis
2011-005856-32Phase 3Completed
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in lupus nephritis (LN) (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Rate of complete or partial renal response at 12, 18, and 24 months. Started Jan 2012; status: completed.
02
Drugs
rituximab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2011-005856-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005856-32.